IQVIA (NYSE:IQV) Posts Earnings Results, Beats Estimates By $0.12 EPS

IQVIA (NYSE:IQV) posted its quarterly earnings data on Tuesday. The medical research company reported $3.15 earnings per share for the quarter, topping analysts’ consensus estimates of $3.03 by $0.12, FiscalAI reports. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The firm had revenue of $4.37 billion during the quarter, compared to analysts’ expectations of $4.30 billion. During the same quarter last year, the firm earned $2.81 EPS. The business’s quarterly revenue was up 8.7% on a year-over-year basis. IQVIA updated its FY 2026 guidance to 12.800-13.000 EPS.

Here are the key takeaways from IQVIA’s conference call:

• Second-quarter results exceeded guidance: Revenue rose 8.7% reported and 8.5% at constant currency, while adjusted EBITDA increased 9.2% and adjusted EPS grew 12.1% to $3.15, driven by operational execution.
• Full-year 2026 guidance was raised for revenue to $17.275–$17.475 billion, adjusted EBITDA to $4.0–$4.05 billion, and adjusted EPS to $12.80–$13.00; the company maintained its expectation for approximately flat adjusted EBITDA margins.
• R&D Solutions bookings strengthened substantially, with net new bookings up 19.3% year over year to $3.15 billion, a 1.22 book-to-bill ratio, and trailing-12-month bookings up 12.9%; management cited broad-based demand, improving win rates, and strong emerging-biopharma funding.
• Commercial Solutions organic growth accelerated to 5%, supported by new drug launches, double-digit growth in engagement services and patient solutions, and rising adoption of AI offerings; management said pipelines, decision timelines, and win rates are all improving.
• Productivity initiatives generated about 90 basis points of underlying margin improvement in the quarter, but pass-through costs created an approximately 80-basis-point headwind. IQVIA is also reviewing its backlog for inactive trials and expects any potential adjustment—currently estimated near 5%—to have no effect on historical results, guidance, or next-12-month revenue-from-backlog metrics.

IQVIA Stock Performance

IQV stock traded down $9.69 during trading on Thursday, hitting $237.87. 652,146 shares of the company traded hands, compared to its average volume of 1,811,362. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.75. IQVIA has a 1 year low of $154.50 and a 1 year high of $251.36. The stock’s 50-day simple moving average is $192.00 and its 200 day simple moving average is $186.89. The company has a market cap of $39.70 billion, a PE ratio of 29.45, a P/E/G ratio of 2.18 and a beta of 1.20.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the stock. Weiss Ratings upgraded shares of IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, July 15th. BMO Capital Markets lifted their price objective on shares of IQVIA from $210.00 to $270.00 and gave the stock an “outperform” rating in a research note on Wednesday. Mizuho lifted their price target on IQVIA from $215.00 to $230.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. JPMorgan Chase & Co. raised their price objective on IQVIA from $225.00 to $285.00 and gave the stock an “overweight” rating in a research note on Wednesday. Finally, Stifel Nicolaus upped their target price on IQVIA from $220.00 to $276.00 and gave the company a “buy” rating in a research report on Wednesday. Thirteen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, IQVIA presently has an average rating of “Moderate Buy” and a consensus target price of $241.88.

IQVIA declared that its Board of Directors has authorized a stock repurchase plan on Thursday, May 7th that authorizes the company to buyback $2.00 billion in shares. This buyback authorization authorizes the medical research company to purchase up to 6.8% of its stock through open market purchases. Stock buyback plans are typically an indication that the company’s management believes its shares are undervalued.

Institutional Trading of IQVIA

A number of hedge funds have recently added to or reduced their stakes in IQV. Brighton Jones LLC grew its position in shares of IQVIA by 244.4% during the 4th quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock valued at $703,000 after acquiring an additional 2,537 shares during the period. Sivia Capital Partners LLC purchased a new stake in shares of IQVIA in the second quarter valued at approximately $514,000. Wedbush Securities Inc. acquired a new stake in shares of IQVIA in the fourth quarter valued at about $217,000. Cim Investment Management Inc. acquired a new stake in IQVIA in the 4th quarter worth about $215,000. Finally, Voleon Capital Management LP purchased a new position in IQVIA in the 2nd quarter valued at $214,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

Key IQVIA News

Here are the key news stories impacting IQVIA this week:

• Positive Sentiment: Strong Q2 results and raised guidance supported the rally. IQVIA reported adjusted earnings of $3.15 per share, ahead of the $3.03 consensus, while revenue reached $4.37 billion versus estimates of $4.30 billion. Revenue increased 8.7% year over year, helped by broad-based growth and record research-and-development bookings. Management raised its full-year 2026 adjusted EPS guidance to $12.80-$13.00. IQV Q2 Earnings Beat Estimates on R&D Bookings, Guidance Raised
• Positive Sentiment: Analyst sentiment improved. JPMorgan raised its price target to $285 from $225 and assigned an overweight rating; Stifel increased its target to $276 and maintained a buy rating; and Robert W. Baird lifted its target to $287 with an outperform rating. Analysts overall maintain a “moderate buy” consensus. IQVIA Receives Consensus Rating of Moderate Buy
• Neutral Sentiment: Fair-value estimates were mixed. Some analysts raised their targets following the earnings beat, but revisions were not uniformly bullish, leaving investors focused on whether IQVIA’s growth outlook justifies its higher valuation. IQVIA Stock Sees Modest Fair Value Lift After Mixed Analyst Target Changes
• Negative Sentiment: Valuation and profit-taking are weighing on the stock. IQVIA trades at approximately 29 times earnings after reaching a new 52-week high following the earnings release. A recent rating downgrade argued that the company is a strong business but that the share price may already reflect much of its growth potential. IQVIA: A Great Business At The Wrong Price

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.